Mark Richards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Richards has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Angèle Gayet-Ageron
Institute of Social and Preventive Medicine (ISPM), University of Bern , Bern
3 shared publications - Khaoula Ben Messaoud
NYU Grossman School of Medicine
3 shared publications - Sara Schroter
BMJ, London, UK
3 shared publications - Alexandra Calmy
HIV Unit, Division of Infectious Diseases, University Hospital Geneva, University of Geneva , Geneva
1 shared publication - Christophe Combescure
Clinical Research Center, Geneva University, Geneva, Switzerland
1 shared publication - Cyril Jaksic
Affiliation Clinical Epidemiology Department, University Hospitals of Geneva, Geneva, Switzerland
1 shared publication
Latest Publications
- Open Access
Assessment of gender and geographical bias in the editorial decision-making process of biomedical journals: A Case-Control study
Objectives: To assess whether the gender (primary) and geographical affiliation (post hoc) of the first and/or last authors of manuscripts is associated with publication decisions after controlling for known confounders. Design: Case-control (1:1) study. Setting: Two large general medical journals and 20 specialist journals. Participants: Original peer reviewed research manuscripts submitted between January 1, 2012, and December 31, 2019. Main outcomes measures and predictor: Manuscripts accepted (cases) and rejected (controls) were compared between women and men first authors (main predictor), and between women and men last authors (secondary predictor). Results: Of 7,000 included manuscripts 6,724 (96.1%) first and 6,768 (96.7%) last authors’ gender were identified; 3,056 (43.7%) and 2,214 (32.7%) were women, respectively. The proportion of women first and last authors were respectively 46.7% (n=1,571) and 32.3% (n=1,093) among cases and 44.2% (n=1,485) and 33.1% (n=1,121) among controls. In univariate analysis, being a woman first author increased the likelihood of acceptance for publication (odds ratio 1.11; 95% confidence interval 1.00 to 1.22). After adjustment for study attributes, then post-hoc variables, the association between the first author’s gender and acceptance for publication became non-significant 1.04 (0.94 to 1.16). The likelihood of acceptance for publication was significantly lower for first authors affiliated to Asia 0.58 (0.48 to 0.70) compared to Europe, and for first author affiliated to upper middle income 0.61 (0.47 to 0.78) and lower middle and low-income 0.65 (0.45 to 0.93) compared to high income countries. Compared to papers where both first and last authors were from the same country, acceptance for publication was significantly higher when both authors were affiliated to different countries from the same geographical and income groups 1.39 (1.09 to 1.77), to different countries, different geographical but same income groups 1.45 (1.14 to 1.84), or to different income groups 1.59 (1.20 to 2.11). The study attributes (design, and funding) were also independently associated with acceptance for publication. Conclusions: The absence of gender inequalities during the editorial decision-making process is reassuring. However, the underrepresentation of first authors affiliated to Asia and low-income countries in manuscripts accepted for publication indicates poor representation of global scientists’ opinion and supports growing demands for improving diversity in biomedical research. Summary boxes: What is already known on this topic?: Published studies have revealed gender inequalities in academia, attainment of leadership positions, successful grant funding and in biomedical research production (including reported research contributions, attainment of key authorship positions in submitted and published manuscripts, membership of editorial boards, and participation in peer review). Geographical inequalities have been reported in biomedical research production, including membership of editorial boards, participation in peer review, and attainment of key authorship positions in submitted and published articles. Diversity in science is associated with better research quality and improved representation of global scientists’ opinions. What this study adds?: Gender inequality toward the first author of original research manuscripts disappeared after adjusting for other important factors related to authorship (first authors’ geographical affiliation and income group), and the study attributes (funding and medical specialty). First authors affiliated to Asia compared to Europe and from low-income compared to high-income countries had a lower chance of being accepted for publication. Geographical and income diverse teams represented by the first and the last authors’ affiliations had a greater chance of being accepted for publication.
Open AccessAssessment of gender and geographical bias in the editorial decision-making process of biomedical journals: A Case-Control study
Objectives: To assess whether the gender (primary) and geographical affiliation (post hoc) of the first and/or last authors of manuscripts is associated with publication decisions after controlling for known confounders. Design: Case-control (1:1) study. Setting: Two large general medical journals and 20 specialist journals. Participants: Original peer reviewed research manuscripts submitted between January 1, 2012, and December 31, 2019. Main outcomes measures and predictor: Manuscripts accepted (cases) and rejected (controls) were compared between women and men first authors (main predictor), and between women and men last authors (secondary predictor). Results: Of 7,000 included manuscripts 6,724 (96.1%) first and 6,768 (96.7%) last authors’ gender were identified; 3,056 (43.7%) and 2,214 (32.7%) were women, respectively. The proportion of women first and last authors were respectively 46.7% (n=1,571) and 32.3% (n=1,093) among cases and 44.2% (n=1,485) and 33.1% (n=1,121) among controls. In univariate analysis, being a woman first author increased the likelihood of acceptance for publication (odds ratio 1.11; 95% confidence interval 1.00 to 1.22). After adjustment for study attributes, then post-hoc variables, the association between the first author’s gender and acceptance for publication became non-significant 1.04 (0.94 to 1.16). The likelihood of acceptance for publication was significantly lower for first authors affiliated to Asia 0.58 (0.48 to 0.70) compared to Europe, and for first author affiliated to upper middle income 0.61 (0.47 to 0.78) and lower middle and low-income 0.65 (0.45 to 0.93) compared to high income countries. Compared to papers where both first and last authors were from the same country, acceptance for publication was significantly higher when both authors were affiliated to different countries from the same geographical and income groups 1.39 (1.09 to 1.77), to different countries, different geographical but same income groups 1.45 (1.14 to 1.84), or to different income groups 1.59 (1.20 to 2.11). The study attributes (design, and funding) were also independently associated with acceptance for publication. Conclusions: The absence of gender inequalities during the editorial decision-making process is reassuring. However, the underrepresentation of first authors affiliated to Asia and low-income countries in manuscripts accepted for publication indicates poor representation of global scientists’ opinion and supports growing demands for improving diversity in biomedical research. Summary boxes: What is already known on this topic?: Published studies have revealed gender inequalities in academia, attainment of leadership positions, successful grant funding and in biomedical research production (including reported research contributions, attainment of key authorship positions in submitted and published manuscripts, membership of editorial boards, and participation in peer review). Geographical inequalities have been reported in biomedical research production, including membership of editorial boards, participation in peer review, and attainment of key authorship positions in submitted and published articles. Diversity in science is associated with better research quality and improved representation of global scientists’ opinions. What this study adds?: Gender inequality toward the first author of original research manuscripts disappeared after adjusting for other important factors related to authorship (first authors’ geographical affiliation and income group), and the study attributes (funding and medical specialty). First authors affiliated to Asia compared to Europe and from low-income compared to high-income countries had a lower chance of being accepted for publication. Geographical and income diverse teams represented by the first and the last authors’ affiliations had a greater chance of being accepted for publication.
- Open Access
Analysis of peer reviewers’ response to invitations by gender and geographical region: cohort study of manuscripts reviewed at 19 biomedical journals before and during covid-19 pandemic
Objectives To describe gender and geographical inequalities in invitations to review and the response to these invitations and to assess whether inequalities increased during the covid-19 pandemic. Design Retrospective cohort study. Setting 19 specialist medical journals and two large general medical journals from BMJ Publishing Group. Population Reviewers invited to review manuscripts submitted between 1 January 2018 and 31 May 2021. The cohort was followed up to 28 February 2022. Main outcome measures Reviewer’s agreement to review. Results A total of 257 025 reviewers were invited (38.6% (88 454/228 869) women), and 90 467 (35.2%) agreed to review. Invited reviewers were mainly (217 682; 84.7%) affiliated with high income countries: Europe (122 414; 47.6%), North America (66 931; 26.0%), Africa (25 735; 10.0%), Asia (22 693; 8.8%), Oceania (16 175; 6.3%), and South America (3076; 1.2%). Independent factors associated with agreement to review were gender (odds ratio 0.89, 95% confidence interval 0.87 to 0.92, for women compared with men), geographical affiliation (2.89, 2.73 to 3.06, for Asia; 3.32, 2.94 to 3.75 for South America; 1.35, 1.27 to 1.43, for Oceania; and 0.35, 0.33 to 0.37, for Africa compared with Europe), and country income (0.47, 0.45 to 0.49, for upper middle income; 5.12, 4.67 to 5.61, for lower middle income; and 4.66, 3.79 to 5.73, for low income compared with high income country). Agreement was also independently associated with editor’s gender (0.96, 0.93 to 0.99, for women compared with men), last author’s geographical affiliation (0.80, 0.78 to 0.83, for Asia; 0.89, 0.85 to 0.94, for Oceania compared with Europe), impact factor (1.78, 1.27 to 2.50, for >10 compared with Conclusions To reduce bias and improve diversity, editors need to identify and implement effective strategies and continually evaluate progress against these to ensure that more women and researchers from upper middle income and low income countries are involved in review.
Open AccessAnalysis of peer reviewers’ response to invitations by gender and geographical region: cohort study of manuscripts reviewed at 19 biomedical journals before and during covid-19 pandemic
Objectives To describe gender and geographical inequalities in invitations to review and the response to these invitations and to assess whether inequalities increased during the covid-19 pandemic. Design Retrospective cohort study. Setting 19 specialist medical journals and two large general medical journals from BMJ Publishing Group. Population Reviewers invited to review manuscripts submitted between 1 January 2018 and 31 May 2021. The cohort was followed up to 28 February 2022. Main outcome measures Reviewer’s agreement to review. Results A total of 257 025 reviewers were invited (38.6% (88 454/228 869) women), and 90 467 (35.2%) agreed to review. Invited reviewers were mainly (217 682; 84.7%) affiliated with high income countries: Europe (122 414; 47.6%), North America (66 931; 26.0%), Africa (25 735; 10.0%), Asia (22 693; 8.8%), Oceania (16 175; 6.3%), and South America (3076; 1.2%). Independent factors associated with agreement to review were gender (odds ratio 0.89, 95% confidence interval 0.87 to 0.92, for women compared with men), geographical affiliation (2.89, 2.73 to 3.06, for Asia; 3.32, 2.94 to 3.75 for South America; 1.35, 1.27 to 1.43, for Oceania; and 0.35, 0.33 to 0.37, for Africa compared with Europe), and country income (0.47, 0.45 to 0.49, for upper middle income; 5.12, 4.67 to 5.61, for lower middle income; and 4.66, 3.79 to 5.73, for low income compared with high income country). Agreement was also independently associated with editor’s gender (0.96, 0.93 to 0.99, for women compared with men), last author’s geographical affiliation (0.80, 0.78 to 0.83, for Asia; 0.89, 0.85 to 0.94, for Oceania compared with Europe), impact factor (1.78, 1.27 to 2.50, for >10 compared with Conclusions To reduce bias and improve diversity, editors need to identify and implement effective strategies and continually evaluate progress against these to ensure that more women and researchers from upper middle income and low income countries are involved in review.
- Open Access
Female authorship of covid-19 research in manuscripts submitted to 11 biomedical journals: cross sectional study
Objective To describe prominent authorship positions held by women and the overall percentage of women co-authoring manuscripts submitted during the covid-19 pandemic compared with the previous two years. Design Cross sectional study. Setting Nine specialist and two large general medical journals. Population Authors of research manuscripts submitted between 1 January 2018 and 31 May 2021. Main outcome measures Primary outcome: first author’s gender. Secondary outcomes: last and corresponding authors’ gender; number (percentage) of women on authorship byline in “pre-pandemic” period (1 January 2018 to 31 December 2019) and in “covid-19” and “non-covid-19” manuscripts during pandemic. Results A total of 63 259 manuscripts were included. The number of female first, last, and corresponding authors respectively were 1313 (37.1%), 996 (27.9%), and 1119 (31.1%) for covid-19 manuscripts (lowest values in Jan-May 2020: 230 (29.4%), 165 (21.1%), and 185 (22.9%)), compared with 8583 (44.9%), 6118 (31.2%), and 7273 (37.3%) for pandemic non-covid-19 manuscripts and 12 724 (46.0%), 8923 (31.4%), and 10 981 (38.9%) for pre-pandemic manuscripts. The adjusted odds ratio of having a female first author in covid-19 manuscripts was Conclusions Women have been underrepresented as co-authors and in prominent authorship positions in covid-19 research, and this gender disparity needs to be corrected by those involved in academic promotion and awarding of research grants. Women attained some prominent authorship positions equally or more frequently than before the pandemic on non-covid-19 related manuscripts submitted at some time points during the pandemic.
Open AccessFemale authorship of covid-19 research in manuscripts submitted to 11 biomedical journals: cross sectional study
Objective To describe prominent authorship positions held by women and the overall percentage of women co-authoring manuscripts submitted during the covid-19 pandemic compared with the previous two years. Design Cross sectional study. Setting Nine specialist and two large general medical journals. Population Authors of research manuscripts submitted between 1 January 2018 and 31 May 2021. Main outcome measures Primary outcome: first author’s gender. Secondary outcomes: last and corresponding authors’ gender; number (percentage) of women on authorship byline in “pre-pandemic” period (1 January 2018 to 31 December 2019) and in “covid-19” and “non-covid-19” manuscripts during pandemic. Results A total of 63 259 manuscripts were included. The number of female first, last, and corresponding authors respectively were 1313 (37.1%), 996 (27.9%), and 1119 (31.1%) for covid-19 manuscripts (lowest values in Jan-May 2020: 230 (29.4%), 165 (21.1%), and 185 (22.9%)), compared with 8583 (44.9%), 6118 (31.2%), and 7273 (37.3%) for pandemic non-covid-19 manuscripts and 12 724 (46.0%), 8923 (31.4%), and 10 981 (38.9%) for pre-pandemic manuscripts. The adjusted odds ratio of having a female first author in covid-19 manuscripts was Conclusions Women have been underrepresented as co-authors and in prominent authorship positions in covid-19 research, and this gender disparity needs to be corrected by those involved in academic promotion and awarding of research grants. Women attained some prominent authorship positions equally or more frequently than before the pandemic on non-covid-19 related manuscripts submitted at some time points during the pandemic.
- Open Access
- 25 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0248119
Drug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species
Burkholderia pseudomallei is a soil-dwelling organism present throughout the tropics. It is the causative agent of melioidosis, a disease that is believed to kill 89,000 people per year. It is naturally resistant to many antibiotics, requiring at least two weeks of intravenous treatment with ceftazidime, imipenem or meropenem followed by 6 months of orally delivered co-trimoxazole. This places a large treatment burden on the predominantly middle-income nations where the majority of disease occurs. We have established a high-throughput assay for compounds that could be used as a co-therapy to potentiate the effect of ceftazidime, using the related non-pathogenic bacterium Burkholderia thailandensis as a surrogate. Optimization of the assay gave a Z’ factor of 0.68. We screened a library of 61,250 compounds and identified 29 compounds with a pIC50 (-log10(IC50)) greater than five. Detailed investigation allowed us to down select to six “best in class” compounds, which included the licensed drug chloroxine. Co-treatment of B. thailandensis with ceftazidime and chloroxine reduced culturable cell numbers by two orders of magnitude over 48 hours, compared to treatment with ceftazidime alone. Hit expansion around chloroxine was performed using commercially available compounds. Minor modifications to the structure abolished activity, suggesting that chloroxine likely acts against a specific target. Finally, an initial study demonstrates the utility of chloroxine to act as a co-therapy to potentiate the effect of ceftazidime against B. pseudomallei. This approach successfully identified potential co-therapies for a recalcitrant Gram-negative bacterial species. Our assay could be used more widely to aid in chemotherapy to treat infections caused by these bacteria.
- 25 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0248119
Open AccessDrug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species
Burkholderia pseudomallei is a soil-dwelling organism present throughout the tropics. It is the causative agent of melioidosis, a disease that is believed to kill 89,000 people per year. It is naturally resistant to many antibiotics, requiring at least two weeks of intravenous treatment with ceftazidime, imipenem or meropenem followed by 6 months of orally delivered co-trimoxazole. This places a large treatment burden on the predominantly middle-income nations where the majority of disease occurs. We have established a high-throughput assay for compounds that could be used as a co-therapy to potentiate the effect of ceftazidime, using the related non-pathogenic bacterium Burkholderia thailandensis as a surrogate. Optimization of the assay gave a Z’ factor of 0.68. We screened a library of 61,250 compounds and identified 29 compounds with a pIC50 (-log10(IC50)) greater than five. Detailed investigation allowed us to down select to six “best in class” compounds, which included the licensed drug chloroxine. Co-treatment of B. thailandensis with ceftazidime and chloroxine reduced culturable cell numbers by two orders of magnitude over 48 hours, compared to treatment with ceftazidime alone. Hit expansion around chloroxine was performed using commercially available compounds. Minor modifications to the structure abolished activity, suggesting that chloroxine likely acts against a specific target. Finally, an initial study demonstrates the utility of chloroxine to act as a co-therapy to potentiate the effect of ceftazidime against B. pseudomallei. This approach successfully identified potential co-therapies for a recalcitrant Gram-negative bacterial species. Our assay could be used more widely to aid in chemotherapy to treat infections caused by these bacteria.